{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T22:40:07Z","timestamp":1784155207484,"version":"3.55.0"},"reference-count":43,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Javna Agencija za Raziskovalno Dejavnost RS (Eng. Slovenian Research Agency)","award":["P1-0170"],"award-info":[{"award-number":["P1-0170"]}]},{"name":"Javna Agencija za Raziskovalno Dejavnost RS (Eng. Slovenian Research Agency)","award":["L3-8203"],"award-info":[{"award-number":["L3-8203"]}]},{"name":"Javna Agencija za Raziskovalno Dejavnost RS (Eng. Slovenian Research Agency)","award":["L3-2622"],"award-info":[{"award-number":["L3-2622"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Calretinin is a promising diagnostic biomarker for malignant mesothelioma (MM), but less is known about its prognostic role. Our aim was to evaluate the association between serum calretinin concentration or genetic factors and the survival or outcome of cisplatin-based chemotherapy in MM. Our study included 265 MM patients. Serum calretinin concentration was determined using ELISA. Patients were genotyped for seven polymorphisms in CALB2, E2F2, MIR335, NRF1, and SEPTIN7 using competitive allele-specific PCR. Nonparametric tests, logistic regression, and survival analysis were used for statistical analysis. Higher serum calretinin concentration was associated with shorter progression-free (PFS) (HR = 1.18 (1.02\u20131.37), p = 0.023) and overall survival (OS) (HR = 1.20 (1.03\u20131.41), p = 0.023), but the association was not significant after adjusting for clinical factors (HR = 1.05 (0.85\u20131.31), p = 0.653 and HR = 1.06 (0.84\u20131.34), p = 0.613, respectively). SEPTIN7 rs3801339 and MIR335 rs3807348 were associated with survival even after adjustment (HR = 1.76 (1.17\u20132.64), p = 0.007 and HR = 0.65 (0.45\u20130.95), p = 0.028, respectively). Calretinin concentration was higher in patients who progressed after treatment with cisplatin-based chemotherapy (1.68 vs. 0.45 ng\/mL, p = 0.001). Calretinin concentration above 0.89 ng\/mL was associated with shorter PFS and OS from the start of chemotherapy (HR = 1.88 (1.28\u20132.77), p = 0.001 and HR = 1.91 (1.22\u20132.97), p = 0.004, respectively), even after adjusting for clinical factors (p &lt; 0.05). MIR335 rs3807348 was associated with a better response to chemotherapy (OR = 2.69 (1.17\u20136.18), p = 0.020). We showed that serum calretinin is associated with survival and chemotherapy treatment outcomes in MM and could serve as a predictive biomarker.<\/jats:p>","DOI":"10.3390\/ijms25010190","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T04:44:40Z","timestamp":1703220280000},"page":"190","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Serum Calretinin and Genetic Variability as a Prognostic and Predictive Factor in Malignant Mesothelioma"],"prefix":"10.3390","volume":"25","author":[{"given":"Cita","family":"Zupanc","sequence":"first","affiliation":[{"name":"Military Medical Unit-Slovenian Army, 1000 Ljubljana, Slovenia"},{"name":"Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alenka","family":"Franko","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"},{"name":"Clinical Institute of Occupational Medicine, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0041-8859","authenticated-orcid":false,"given":"Danijela","family":"\u0160trbac","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"},{"name":"Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viljem","family":"Kova\u010d","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"},{"name":"Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6707-6649","authenticated-orcid":false,"given":"Vita","family":"Dol\u017ean","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Laboratory, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5673-4458","authenticated-orcid":false,"given":"Katja","family":"Gori\u010dar","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Laboratory, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"\u0160trbac, D., and Dol\u017ean, V. (2022). Novel and Future Treatment Options in Mesothelioma: A Systematic Review. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23041975"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.21037\/tlcr-19-488","article-title":"Does size matter?\u2014A population-based analysis of malignant pleural mesothelioma","volume":"9","author":"He","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2478\/v10019-012-0032-0","article-title":"Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients","volume":"46","author":"Kovac","year":"2012","journal-title":"Radiol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Rondon, L., Fu, R., and Patel, M.R. (2023). Success of Checkpoint Blockade Paves the Way for Novel Immune Therapy in Malignant Pleural Mesothelioma. Cancers, 15.","DOI":"10.3390\/cancers15112940"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Deiana, C., Fabbri, F., Tavolari, S., Palloni, A., and Brandi, G. (2023). Improvements in Systemic Therapies for Advanced Malignant Mesothelioma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310415"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"11795549231178173","DOI":"10.1177\/11795549231178173","article-title":"Pleural Mesothelioma in the Era of Immunotherapy","volume":"17","author":"Chevallier","year":"2023","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S353","DOI":"10.21037\/jtd.2017.10.132","article-title":"Serum mesothelin and other biomarkers: What have we learned in the last decade?","volume":"10","author":"Cristaudo","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","article-title":"Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma","volume":"367","author":"Pass","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1515\/raon-2015-0019","article-title":"Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma","volume":"49","author":"Kovac","year":"2015","journal-title":"Radiol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"210057","DOI":"10.1183\/16000617.0057-2021","article-title":"Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: A systematic review and meta-analysis","volume":"30","author":"Schillebeeckx","year":"2021","journal-title":"Eur. Respir. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S369","DOI":"10.21037\/jtd.2017.10.158","article-title":"Overexpressed genes in malignant pleural mesothelioma: Implications in clinical management","volume":"10","author":"Barone","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"671298","DOI":"10.3389\/fphar.2021.671298","article-title":"Extracellular Vesicles: A Novel Tool Facilitating Personalized Medicine and Pharmacogenomics in Oncology","volume":"12","author":"Goricar","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Gori\u010dar, K., Holcar, M., Mavec, N., Kova\u010d, V., Lenassi, M., and Dol\u017ean, V. (2021). Extracellular Vesicle Enriched miR-625-3p Is Associated with Survival of Malignant Mesothelioma Patients. J. Pers. Med., 11.","DOI":"10.3390\/jpm11101014"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Blum, W., Pecze, L., Rodriguez, J.W., Steinauer, M., and Schwaller, B. (2018). Regulation of calretinin in malignant mesothelioma is mediated by septin 7 binding to the CALB2 promoter. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4385-7"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"W\u00f6rthm\u00fcller, J., Salicio, V., Oberson, A., Blum, W., and Schwaller, B. (2019). Modulation of Calretinin Expression in Human Mesothelioma Cells Reveals the Implication of the FAK and Wnt Signaling Pathways in Conferring Chemoresistance towards Cisplatin. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20215391"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e039079","DOI":"10.1136\/bmjopen-2020-039079","article-title":"Re-evaluation of potential predictors of calretinin and mesothelin in a population-based cohort study using assays for the routine application in clinical medicine","volume":"11","author":"Casjens","year":"2021","journal-title":"BMJ Open"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"32643","DOI":"10.1038\/srep32643","article-title":"Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo","volume":"6","author":"Greening","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Zupanc, C., Franko, A., \u0160trbac, D., Dodi\u010d Fikfak, M., Kova\u010d, V., Dol\u017ean, V., and Gori\u010dar, K. (2021). Serum Calretinin as a Biomarker in Malignant Mesothelioma. J. Clin. Med., 10.","DOI":"10.3390\/jcm10214875"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"883","DOI":"10.7150\/ijms.23939","article-title":"Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population","volume":"15","author":"Pesch","year":"2018","journal-title":"Int. J. Med. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Johnen, G., Gawrych, K., Raiko, I., Casjens, S., Pesch, B., Weber, D.G., Taeger, D., Lehnert, M., Kollmeier, J., and Bauer, T. (2017). Calretinin as a blood-based biomarker for mesothelioma. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3375-5"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/bjc.2014.478","article-title":"Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales","volume":"111","author":"Linton","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.pathol.2016.08.003","article-title":"Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma","volume":"48","author":"Thapa","year":"2016","journal-title":"Pathology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1097\/JTO.0b013e31822a3740","article-title":"Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy","volume":"6","author":"Kao","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1002\/ijc.32676","article-title":"Serum calretinin as an independent predictor for platinum resistance and prognosis in ovarian cancer","volume":"146","author":"Link","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e017104","DOI":"10.1136\/bmjopen-2017-017104","article-title":"Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: Results from a population-based cohort study","volume":"7","author":"Casjens","year":"2017","journal-title":"BMJ Open"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1038\/srep09507","article-title":"Diagnostic accuracy of calretinin for malignant mesothelioma in serous effusions: A meta-analysis","volume":"5","author":"Li","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"21272","DOI":"10.18632\/oncotarget.7114","article-title":"Identification of cis- and trans-acting elements regulating calretinin expression in mesothelioma cells","volume":"7","author":"Kapaklikaya","year":"2016","journal-title":"Oncotarget"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nature06487","article-title":"Endogenous human microRNAs that suppress breast cancer metastasis","volume":"451","author":"Tavazoie","year":"2008","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Lehnert, M., Weber, D.G., Taeger, D., Raiko, I., Kollmeier, J., Stephan-Falkenau, S., Br\u00fcning, T., Johnen, G., Brik, A., and Burek, K. (2020). Determinants of plasma calretinin in patients with malignant pleural mesothelioma. BMC Res. Notes, 13.","DOI":"10.1186\/s13104-020-05187-y"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.21037\/tlcr.2019.11.29","article-title":"Application of immunohistochemistry in diagnosis and management of malignant mesothelioma","volume":"9","author":"Chapel","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_31","first-page":"14","article-title":"The immunohistochemical characterization of sarcomatoid malignant mesothelioma of the pleura","volume":"1","author":"Chirieac","year":"2011","journal-title":"Am. J. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Calthorpe, L., Romero-Hernandez, F., Miller, P., Conroy, P.C., Hirose, K., Kim, A., Kirkwood, K., Nakakura, E., Corvera, C., and Maker, A.V. (2022). Contemporary Trends in Malignant Peritoneal Mesothelioma: Incidence and Survival in the United States. Cancers, 15.","DOI":"10.3390\/cancers15010229"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41698-021-00182-3","article-title":"A multi-omics study links TNS3 and SEPT7 to long-term former smoking NSCLC survival","volume":"5","author":"Shen","year":"2021","journal-title":"NPJ Precis. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1111\/jcmm.13623","article-title":"The role of septin 7 in physiology and pathological disease: A systematic review of current status","volume":"22","author":"Wang","year":"2018","journal-title":"J. Cell Mol. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"61587","DOI":"10.18632\/oncotarget.11402","article-title":"The requirement of SEPT2 and SEPT7 for migration and invasion in human breast cancer via MEK\/ERK activation","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41431-023-01346-4","article-title":"Genetic factors influence serum calretinin levels in asbestos-related diseases. Abstracts from the 55th European Society of Human Genetics (ESHG) Conference","volume":"31","author":"Zupanc","year":"2023","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.2147\/OTT.S305098","article-title":"Functions and Targets of miR-335 in Cancer","volume":"14","author":"Ye","year":"2021","journal-title":"Oncol. Targets Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e21369","DOI":"10.1097\/MD.0000000000021369","article-title":"Correlation of microRNA-335 expression level with clinical significance and prognosis in non-small cell lung cancer","volume":"99","author":"Huo","year":"2020","journal-title":"Medicine"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Lamberti, M., Capasso, R., Lombardi, A., Di Domenico, M., Fiorelli, A., Feola, A., Perna, A.F., Santini, M., Caraglia, M., and Ingrosso, D. (2015). Two Different Serum MiRNA Signatures Correlate with the Clinical Outcome and Histological Subtype in Pleural Malignant Mesothelioma Patients. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0135331"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1002\/cam4.1682","article-title":"MiR-335-5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2","volume":"7","author":"Liu","year":"2018","journal-title":"Cancer Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Raiko, I., Sander, I., Weber, D.G., Raulf-Heimsoth, M., Gillissen, A., Kollmeier, J., Scherpereel, A., Bruning, T., and Johnen, G. (2010). Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-242"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"W556","DOI":"10.1093\/nar\/gkz430","article-title":"GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis","volume":"47","author":"Tang","year":"2019","journal-title":"Nucleic Acids Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/1\/190\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:40:14Z","timestamp":1760132414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/1\/190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["ijms25010190"],"URL":"https:\/\/doi.org\/10.3390\/ijms25010190","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,22]]}}}